Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03588728 · ClinicalTrials.gov registry record · NA
tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia
A NA study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT03588728: Clinical Trial NA study, sponsored by University of Pittsburgh.
NCT03588728 is a NA study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 39 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03588728, a NA study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study is being done to develop new methods to help smokers with schizophrenia to successfully reduce their smoking and/or quit. This is not a treatment study, but will help find new techniques to create better treatments. Specifically, the investigators are interested in learning more about how thoughts and attention problems associated with schizophrenia might play a role in smoking, as well as the impact of cognitive (thinking, reasoning, and remembering) training and brain stimulation on these symptoms and on actual smoking.
Primary Outcome
the MATRICS Consensus battery (MCCB) is a cognitive battery of tests for assessing cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of measures. Change in cognitive measures of MATRICS Consensus Cognitive Battery (MCCB). Post-intervention minus baseline. Scale is scored 0-100. Difference score range is (-100 to 100) with positive scores reflecting improvement.
Interventions
- BEHAVIORAL Cognitive Remediation (CR)
- OTHER Transcranial Direct Current Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2020-03-12 |
| Phase | NA |
Why NCT03588728 stopped before completion
NCT03588728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Cognitive Remediation (CR) is the first listed.
NCT03588728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03588728 about?
NCT03588728 is a clinical study titled "tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia". This study is being done to develop new methods to help smokers with schizophrenia to successfully reduce their smoking and/or quit. This is not a treatment study, but will help find new techniques to create better treatments. Specifically, the investigators are interested in learning more about how...
What is the current status of trial NCT03588728?
This trial is currently terminated. It is a NA study. The enrollment target is 39 participants. The study started on 2018-07-23. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT03588728?
The interventions under investigation include: Cognitive Remediation (CR) (BEHAVIORAL), Transcranial Direct Current Stimulation (OTHER).
Who is sponsoring clinical trial NCT03588728?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03588728's enrollment target sits among peer trials
39 1536th of 2000 higher than 463 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI